A Study to Evaluate the Efficacy and Safety of Gantenerumab in Participants at Risk for or at the Earliest Stages of Alzheimer's Disease (AD)
Stopped early · Phase 3 · Has a placebo group
Conditions studied: Alzheimers Disease
In brief
A study to evaluate the efficacy and safety of gantenerumab in amyloid-positive, cognitively unimpaired participants at risk for or at the earliest stages of AD. The planned number of participants for this study is approximately 1200 participants randomized in a 1:1 ratio to receive either gantenerumab or placebo (600 participants randomized to gantenerumab and 600 participants randomized to placebo).
Key facts
- Study ID
- NCT05256134
- Run by
- Hoffmann-La Roche
- People needed
- 25
- Starts
- 2022-04-19
- Expected to finish
- 2023-03-13
- Last updated by the study team
- 2025-06-12
Who can join
Age: 60 and older, up to 80. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Charter Research - Winter Park/Orlando — Orlando, Florida, United States
- Progressive Medical Research — Port Orange, Florida, United States
- Alzheimer's Research and Treatment Center — Stuart, Florida, United States
- Charter Research - Lady Lake/The Villages — The Villages, Florida, United States
- Alzheimer?s Research and Treatment Center — Wellington, Florida, United States
- Premiere Research Institute — West Palm Beach, Florida, United States
- Center for Advanced Research & Education — Gainesville, Georgia, United States
- Great Lakes Clinical Trials — Chicago, Illinois, United States
- Via Christi Research — Wichita, Kansas, United States
- Tandem Clinical Research, LLC — Marrero, Louisiana, United States
- Quest Research Institute — Farmington Hills, Michigan, United States
- University of Nebraska Medical Center; Dept of Neurological Sciences — Omaha, Nebraska, United States
- The Cognitive and Research Center of New Jersey — Springfield, New Jersey, United States
- Velocity Clinical Research — East Syracuse, New York, United States
- Alzheimer's Memory Center — Matthews, North Carolina, United States
- Ohio State University; College of Medicine — Columbus, Ohio, United States
- Senior Adults Specialty Research — Austin, Texas, United States
- Kerwin Medical Center — Dallas, Texas, United States
- Re:Cognition Health — Fairfax, Virginia, United States
- Instituto Kremer — Córdoba, Argentina
- KaRa Institute of Neurological Diseases — Macquarie Park, New South Wales, Australia
- Heidelberg Repatriation Hospital; Medical and Cognitive Research Centre — Heidelberg West, Victoria, Australia
- Australian Alzheimer's Research Foundation — Nedlands, Western Australia, Australia
- Okanagan Clinical Trials — Kelowna, British Columbia, Canada
- Renstar Medical Research — Ocala, Florida, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.